Lupin announced the completion of its acquisition of VISUfarma B.V. (VISUfarma), a leading European specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). The acquisition represents a significant milestone in Lupin`s strategy to expand its specialty care portfolio and strengthen its presence in Europe. The integration of VISUfarma has significantly expanded Lupin`s ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health, and specialty nutraceuticals. VISUfarma`s strong commercial footprint across key European markets, including Italy, the UK, Spain, Germany, and France, is strengthened by a highly experienced team with deep ophthalmology expertise, trusted relationships, and strong local market insight. VISUfarma enhances Lupin`s ability to address the growing global demand for innovative eye care solutions, driven by an ageing population and the growing burden of diabetes-related eye complications.

Lupin announced that Multicare Pharmaceuticals Philippines, Inc. (MPPI), a subsidiary of Nanomi B.V., the Netherlands (Nanomi), which is a wholly owned subsidiary of the Company, has bought back 2,813,811 equity shares from some of its existing shareholders. Nanomi did not participate in the said buyback. This has resulted in increase in the shareholding of Nanomi in MPPI from 51% to 56.28% effective today.Powered by Capital Market - Live News

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Pitolisant Tablets, 4.45mg and 17.8mg. This product would be manufactured at Lupin`s Nagpur facility in India. The U.S. FDA has tentatively approved Lupin`s Pitolisant Tablets 4.45mg and 17.8 mg as bioequivalent to Wakix� for the indication in the approved labeling. Powered by Capital Market - Live News

Lupin has allotted 135,892 equity shares under ESOP on 24 March 2026. With this allotment, the paid up equity share capital has increased to Rs 91,43,58,222 consisting of 45,71,79,111 equity shares of Rs 2/- each.Powered by Capital Market - Live News

Lupin Manufacturing Solutions (LMS), a global CRDMO and subsidiary of global pharma major Lupin, today announced a strategic expansion of its Dabhasa manufacturing facility, marking a significant step toward scaling its peptide building-blocks platform and CRDMO capabilities. The expanded infrastructure features a new block to enhance existing CRDMO capabilities supported by dedicated peptide manufacturing capacity across two additional specialized units. These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions. Powered by Capital Market - Live News